See more : BitFrontier Capital Holdings, Inc. (BFCH) Income Statement Analysis – Financial Results
Complete financial analysis of ICARES Medicus, Inc. (6612.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICARES Medicus, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- GT Biopharma, Inc. (GTBP) Income Statement Analysis – Financial Results
- Zhejiang Yingfeng Technology Co., Ltd. (605055.SS) Income Statement Analysis – Financial Results
- G6 Materials Corp. (GPHBF) Income Statement Analysis – Financial Results
- SKAGEN – Global (SKIGLO.CO) Income Statement Analysis – Financial Results
- New Vista Acquisition Corp (NVSAW) Income Statement Analysis – Financial Results
ICARES Medicus, Inc. (6612.TWO)
About ICARES Medicus, Inc.
ICARES Medicus, Inc., a nano-medical material company, focuses on the research and development, manufacture, and sale of ophthalmic medical materials in Taiwan and internationally. It provides ophthalmic medical materials, including intraocular lens for the treatment of cataract, myopia, hyperopia, presbyopia, or astigmatism; and surgical implantation systems, as well as related technical services. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 605.45M | 511.85M | 393.92M | 362.67M | 419.36M |
| Cost of Revenue | 123.05M | 94.41M | 71.04M | 70.80M | 87.53M |
| Gross Profit | 482.40M | 417.44M | 322.89M | 291.87M | 331.84M |
| Gross Profit Ratio | 79.68% | 81.56% | 81.97% | 80.48% | 79.13% |
| Research & Development | 177.45M | 133.08M | 104.87M | 98.25M | 91.16M |
| General & Administrative | 158.75M | 131.64M | 110.89M | 100.07M | 102.49M |
| Selling & Marketing | 27.56M | 25.59M | 16.12M | 16.25M | 20.09M |
| SG&A | 186.31M | 157.23M | 127.00M | 116.32M | 135.12M |
| Other Expenses | 0.00 | 21.94M | -12.07M | 758.00K | 0.00 |
| Operating Expenses | 373.84M | 290.30M | 231.87M | 214.57M | 226.29M |
| Cost & Expenses | 496.89M | 384.71M | 302.91M | 285.36M | 313.81M |
| Interest Income | 2.38M | 1.22M | 405.00K | 929.00K | 3.21M |
| Interest Expense | 7.17M | 576.00K | 829.00K | 976.00K | 1.17M |
| Depreciation & Amortization | 43.73M | 28.31M | 28.69M | 30.05M | 16.47M |
| EBITDA | 165.54M | 174.42M | 105.87M | 103.58M | 122.02M |
| EBITDA Ratio | 27.34% | 34.08% | 26.88% | 28.56% | 29.10% |
| Operating Income | 118.64M | 146.11M | 77.18M | 73.53M | 105.55M |
| Operating Income Ratio | 19.60% | 28.55% | 19.59% | 20.27% | 25.17% |
| Total Other Income/Expenses | -5.35M | 18.40M | -17.82M | 234.00K | 3.46M |
| Income Before Tax | 113.29M | 143.11M | 73.19M | 73.76M | 109.01M |
| Income Before Tax Ratio | 18.71% | 27.96% | 18.58% | 20.34% | 25.99% |
| Income Tax Expense | 48.86M | 32.72M | 35.82M | 36.84M | 40.52M |
| Net Income | 97.73M | 128.91M | 58.60M | 51.91M | 81.02M |
| Net Income Ratio | 16.14% | 25.19% | 14.88% | 14.31% | 19.32% |
| EPS | 2.81 | 3.81 | 1.72 | 1.53 | 2.21 |
| EPS Diluted | 2.54 | 3.79 | 1.72 | 1.52 | 2.20 |
| Weighted Avg Shares Out | 34.82M | 34.29M | 34.16M | 33.97M | 36.83M |
| Weighted Avg Shares Out (Dil) | 38.50M | 34.45M | 34.16M | 34.07M | 36.86M |
Source: https://incomestatements.info
Category: Stock Reports